New blood test may spot liver cancer sooner in High-Risk patients
NCT ID NCT03311152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each test identified cancer. The goal is to find a more accurate, non-invasive way to catch liver cancer early in people with cirrhosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Nancy (CHRU de Nancy)
Vandœuvre-lès-Nancy, 54511, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can everyday drugs shield the liver from Cirrhosis's worst threats?